Overview

Pentoxifylline in Patients With Ulcerative Colitis

Status:
NOT_YET_RECRUITING
Trial end date:
2027-02-20
Target enrollment:
Participant gender:
Summary
Ulcerative colitis (UC) is a persistent, idiopathic form of inflammatory bowel disease (IBD) marked by uninterrupted inflammation of the colon's mucosal lining, usually starting at the rectum and progressing proximally in a continuous manner. It manifests clinically with recurrent episodes of abdominal pain, bloody diarrhea, urgency, tenesmus, and weight loss. The precise cause of UC is still unknown; however, it is thought to arise from a multifactorial interaction involving genetic susceptibility, immune system dysregulation, disturbances in gut microbiota composition, and various environmental factors.
Phase:
PHASE2
Details
Lead Sponsor:
Ihab Elsayed Hassan
Treatments:
Mesalamine
Pentoxifylline